Detailansicht

Wissensnetz

Person

Peter Valent (1962-)

Arzt

Name	Peter Valent
Zeit	1962- (Lebensdaten)
Ort	Wien (Wirkungsort) Österreich
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf) Hämatologe Hochschullehrer
Variante	P. Valent
Beziehung	Universitätsklinik für Innere Medizin I (Wien)
Quelle	Wikipedia: https://de.wikipedia.org/w/index.php?title=Peter_Valent&oldid=218799792 (Stand: 02.02.2022)
Datensatztyp	Person
GND-Nummer	1112048979
Datensatz-ID	1112048979
Beteiligt an alle anzeigen Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification Clonal medicine targeting DNA damage response eradicates leukemia Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022 Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research Identification of a leukemia-initiating stem cell in human mast cell leukemia Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis MARS: mutation-adjusted risk score for advanced systemic mastocytosis Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer Major response of PNH to an AML chemotherapy protocol Pharmacologic inhibition of STAT5 in acute myeloid leukemia NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm ICON: Eosinophil Disorders European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation Therapiekonzepte für AML-Patienten über 60 Jahre : Spezifische Faktoren und Probleme müssen in Betracht gezogen werden Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy The European Competence Network on Mastocytosis Treatment concepts for elderly patients with acute myeloid leukemia Signal Transduction—Associated and Cell Activation—Linked Antigens Expressed in Human Mast Cells

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Peter Valent (1962-)

Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Clonal medicine targeting DNA damage response eradicates leukemia

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022

Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study

An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis

Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research

Identification of a leukemia-initiating stem cell in human mast cell leukemia

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer

Major response of PNH to an AML chemotherapy protocol

Pharmacologic inhibition of STAT5 in acute myeloid leukemia

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

ICON: Eosinophil Disorders

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation

Therapiekonzepte für AML-Patienten über 60 Jahre : Spezifische Faktoren und Probleme müssen in Betracht gezogen werden

Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy

The European Competence Network on Mastocytosis

Treatment concepts for elderly patients with acute myeloid leukemia

Signal Transduction—Associated and Cell Activation—Linked Antigens Expressed in Human Mast Cells